Image

Global Rare Biomarkers Market – Industry Trends and Forecast to 2029

  • Healthcare
  • Upcoming Report
  • Aug 2022
  • Global
  • 350 Pages
  • No of Tables: 220
  • No of Figures: 60
  • Healthcare
  • Upcoming Report
  • Aug 2022
  • Global
  • 350 Pages
  • No of Tables: 220
  • No of Figures: 60

Global Rare Biomarkers Market, By Product (Circulating Cell Free DNA, Circulating Tumor Cells, Exosomes/Extracellular Vesicles, Circulating Cell Free RNA, and Others), End Use (Research, and Diagnostics) – Industry Trends and Forecast to 2029.

Rare Biomarkers Market

Rare Biomarkers Market Analysis and Size

A biological molecule or gene is referred to as a biomarker when it is utilised to precisely and effectively assess pharmacologic reactions, pathogenic processes, and biological processes. Biomarkers, which are often referred to as molecular markers or signature molecules, are present in tissue, various bodily fluids, and blood. Biomarkers are frequently used to monitor the body's response to a specific treatment for a disease or condition. They help doctors diagnose patients' health and make wise therapeutic decisions. The use of biomarkers as stand-in endpoints during the development of treatments has been authorised by the U.S. Food and Drug Administration (FDA). The industry is being driven by a significant rise in the number of studies showing how circulating biomarkers are used to control disease. The market's revenue growth has been significantly impacted by factors including rising demand for personalised medicine and rising desire for non-invasive disease treatment.

Data Bridge Market Research analyses that the rare biomarkers market which was USD 12.4 billion in 2021, would rocket up to USD 34.39 billion by 2029, and is expected to undergo a CAGR of 13.6% during the forecast period 2022 to 2029. The market report curated by the Data Bridge Market Research team includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Market Definition

Biomarkers (also known as signature molecule or molecular marker) are basically utilized to check how the body responds to a treatment of any condition or disease and assist in examining the organ functions and other health conditions. These play a vital role in the imaging technology so that they can provide clear imaging of oncology tumors and other problems.

Rare Biomarkers Market Scope and Segmentation

Report Metric

Details

Forecast Period

2022 to 2029

Base Year

2021

Historic Years

2020 (Customizable to 2014 - 2019)

Quantitative Units

Revenue in USD Billion, Volumes in Units, Pricing in USD

Segments Covered

Product (Circulating Cell Free DNA, Circulating Tumor Cells, Exosomes/Extracellular Vesicles, Circulating Cell Free RNA, and Others), End Use (Research, and Diagnostics)

Countries Covered

U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America

Market Players Covered

F. Hoffmann-La Roche Ltd. (U.S.), Thermo Fisher Scientific Inc. (U.S.), Abbott (U.S.), QIAGEN (Germany), PerkinElmer, Inc. (U.S), Merck KGaA (Germany ), Bio-Rad Laboratories, Inc. (U.S.), Enzo Biochem, Inc. (U.S.), Charles River Laboratories International, Inc. (U.S.), Eurofins Scientific (Luxembourg), Agilent Technologies, Inc. (U.S.), Bruker (U.S.), Siemens (U.S.), Epigenomics AG (Germany), General Electric (U.S.)

Market Opportunities

  • Increased R&D activities
  • Increasing use of biomarker technologies in drug development

Rare Biomarkers Market Dynamics

Drivers

  • Increasing number of patients with rising population

The rising need for non-invasive cancer diagnostics is one of the major factors propelling the rare biomarkers market forward. Furthermore, the rising number of cancer patients and research programmes, as well as the rise in unhealthy lifestyles and chronic diseases like as diabetes and cardiovascular problems, all contribute to the market's overall growth.

  • Increasing number of CROs

The low cost of clinical trials in emerging countries, the increasing prevalence of cancer, and new research initiatives are expected to accelerate the rare biomarkers market's growth during the forecast period. The use of minimally invasive techniques for the identification of conditions such as cancer, represents an opportunity that will start the development of the rare biomarkers market in the forecast period 2022 to 2029.

  • Growing importance of companion diagnostics

 The rare biomarkers market is expected to rise due to reasons such as rising cancer prevalence worldwide, increased finances and grants for biomarker research, and continual product improvements.

Opportunities

Governments are also promoting biomarker technologies across Europe, which are boosting financing for biomarker research. As a result, increased R&D activities will likely boost the rare biomarkers market forward in the coming years. Furthermore, the increasing use of biomarker technologies in drug development and genome mapping studies, as well as a growing inclination for tailored medications, are driving the rare biomarkers market.

Restraints/Challenges

However, obstacles such as high investment requirements, high treatment costs, and expensive capital expenditure on equipment are expected to stymie market expansion, as are technical challenges with sample collection and a lack of suitable reimbursement.

This rare biomarkers market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the rare biomarkers market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

COVID-19 Impact on Rare Biomarkers Market

The COVID-19 outbreak caused widespread disruption in nearly every industry. However, this is not the case in the biomarker industry, as biomarkers are critical in the development of chronic-care medicines, where the government and pharmaceutical firms will invest heavily, stifling market growth. Various studies have been undertaken, and biomarkers have been discovered to have an important role in diagnosing and treating COVID-19.

Recent Development

  • In February 2022, Abbott Laboratories released Lingo, a consumer bio wearable that can track important body signals and help consumers better understand and improve their overall health. It could allow biohackers to use a continuous stream of data rather than periodic finger-prick tests, urine samples, and breath readings.

  • In February 2022, OncoDNA, a genomic and prognostic business, released the OncoDEEP kit. The kit provides a complete workflow solution that allows laboratories with NGS capabilities to undertake thorough biomarker testing, perform advanced data analysis, and assist oncologists in providing the most effective and customised cancer treatments for their patients.

  • In December 2020, Neoantigen Presentation Score (NEOPS), a neoantigen-based composite biomarker for cancer immunotherapy response, was introduced by Personalis, Inc. To more accurately forecast how a patient will respond to cancer therapy, NEOPS integrates research from Personalis' tumour neoantigen prediction tool SHERPA with immune evasion mechanisms. This should accelerate market expansion.

Global Rare Biomarkers Market Scope

The rare biomarkers market is segmented on the basis of product and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Product

  • Circulating Cell Free DNA (ccfDNA)
  • Circulating Tumor Cells (CTCs)
  • Exosomes/Extracellular Vesicles
  • Product
  • Isolation Kits and Reagents
  • Blood Collection Tubes
  • Systems
  • Specimen Type
  • Serum/Plasma
  • Others
  • Nucleic Acid and Other Biomolecules
  • RNA
  • DNA
  • Others
  • Application
  • NIPT
  • Oncology
  • Transcriptomics
  • Pharmacogenomics
  • Transplant Rejection
  • Population Screening
  • Cardiovascular Diseases
  • Other Applications
  • Circulating Cell Free RNA (ccfRNA) / miRNA

End-use

  • Research
  • Research Labs/CROs
  • Academic Institutes
  • Diagnostics
  • Laboratories
  • Hospitals
  • Prenatal Clinics

Rare Biomarkers Market Regional Analysis/Insights

The rare biomarkers market is analysed and market size insights and trends are provided by country, product and end-user as referenced above.

The countries covered in the rare biomarkers market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America is dominating the market which is essential determinants adding to the comprehensive income portion of this geographical exchange for rare biomarkers individual acquiring and stabilization introduce the appearance of extensive consumer support copulated with an abundant number of FDA-approved commodities.

Asia-Pacific is expected to grow the market in the forecast period of 2022-2029.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Healthcare Infrastructure Growth Installed base and New Technology Penetration

The rare biomarkers market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for rare biomarkers market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the rare biomarkers market. The data is available for historic period 2010-2020.

Competitive Landscape and Rare Biomarkers Market Share Analysis

The rare biomarkers market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to rare biomarkers market.

Some of the major players operating in the rare biomarkers market are:

  • F. Hoffmann-La Roche Ltd. (U.S.)
  • Thermo Fisher Scientific Inc. (U.S.)
  • Abbott (U.S.)
  • QIAGEN (Germany)
  • PerkinElmer, Inc. (U.S.)
  • Merck KGaA (Germany )
  • Bio-Rad Laboratories, Inc. (U.S.)
  • Enzo Biochem, Inc. (U.S.)
  • Charles River Laboratories International, Inc. (U.S.)
  • Eurofins Scientific (Luxembourg)
  • Agilent Technologies, Inc. (U.S.)
  • Bruker (U.S.)
  • Siemens (U.S.)
  • Epigenomics AG (Germany)
  • General Electric (U.S.)


SKU-

Why Choose Us


Frequently Asked Questions

The rare biomarkers market value is expected USD 34.39 billion by 2029.
The rare biomarkers market is projected to grow at a CAGR of 13.6% during the forecast period.
On the basis of product, the Rare Biomarkers Market is segmented into Circulating Cell Free DNA, Circulating Tumor Cells, Exosomes/Extracellular Vesicles, Circulating Cell Free RNA, and Others.
The major players operating in the Rare Biomarkers Market are F. Hoffmann-La Roche Ltd. (U.S.), Thermo Fisher Scientific Inc. (U.S.), Abbott (U.S.), QIAGEN (Germany), PerkinElmer, Inc. (U.S), Merck KGaA (Germany ), Bio-Rad Laboratories, Inc. (U.S.), Enzo Biochem, Inc. (U.S.), Charles River Laboratories International, Inc. (U.S.), Eurofins Scientific (Luxembourg), Agilent Technologies, Inc. (U.S.), Bruker (U.S.), Siemens (U.S.), Epigenomics AG (Germany), General Electric (U.S.).